New drug candidate for MS shows promise in Phase I trial
FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS). “Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,”… Read More